Results 121 to 130 of about 630,325 (166)

Immune thrombocytopenia: Evolving mechanistic understanding and clinical development of new therapies. [PDF]

Tzu Chi Med J
Huang SC, Shen CL, Wu YF.
europepmc   +1 more source

Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases. [PDF]

Proc Natl Acad Sci U S A
Sanmarco LM, Pellerin A, Green T, Plasencia A, Anderson JM, Le N, Newton A, Chen J, Ramello MC, Peckner R, Manasson J, Xing Y, Vital H, Higginson-Scott N, Sundy JS, Otipoby KL, Mascanfroni ID.   +16 more
europepmc   +1 more source

Emerging targeted therapies for primary immune thrombocytopenia: novel agents, combination strategies, and future directions. [PDF]

Front Pharmacol
Wang Z, Yang W, Xu N, Ma L, Wang A, Liu B.   +5 more
europepmc   +1 more source

Evolving Paradigms in the Management of Primary Immune Thrombocytopenia in Adults: From Corticosteroids to Targeted Therapies. [PDF]

Mediterr J Hematol Infect Dis
Martino M, Giordano L, Greve MB, Marafioti V, Alati C.   +4 more
europepmc   +1 more source

Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis. [PDF]

Muscle Nerve
Abi Aoun M, Beauvais D, Barnay M, Violleau MH, Mathis S, Duval F, Sole G.   +6 more
europepmc   +1 more source

Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering. [PDF]

Drugs
Li S, Gao Y, Zhu CG, Li JJ.
europepmc   +1 more source

Current status and challenges of biologic targeted therapy for myasthenia gravis in China. [PDF]

Intractable Rare Dis Res
Gu S, Zhao C.
europepmc   +1 more source

Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis

Frontiers in Immunology
Ina Zhang, Jeroen P. Jansen, Benjamin J. Yungher, Adrian Kielhorn, Karen S. Yee   +4 more
doaj   +1 more source

Bridging the Gap in Sjögren's Disease: A Comprehensive Review of Unmet Needs, Diagnostic Challenges, and Emerging Therapeutic Strategies. [PDF]

Cureus
Aung T.
europepmc   +1 more source

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). [PDF]

Front Neurol
Meisel A, Antozzi C, Bhavaraju-Sanka R, De Bleecker JL, Huang WY, Jimenez RH, Verhamme FM, Jiang M, Liu L, Korobko D, Kostera-Pruszczyk A, Utsugisawa K, Verschuuren JJGM, Vu T, Wiendl H, Howard JF.   +15 more
europepmc   +1 more source